Literature DB >> 30814337

Driving CAR T cell translation forward.

Liora Schultz1, Crystal Mackall2,3,4.   

Abstract

Successes in CAR T cell translation have propelled their commercial launch, but expanding the impact of cancer immunotherapies remains challenging.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30814337     DOI： 10.1126/scitranslmed.aaw2127

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  17 in total

Review 1.  Fueling chimeric antigen receptor T cells with cytokines.

Authors:  Jin Jin; Jiali Cheng; Meijuan Huang; Hui Luo; Jianfeng Zhou
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.

Authors:  Brooke Prinzing; Caitlin C Zebley; Christopher T Petersen; Yiping Fan; Alejandro Allo Anido; Zhongzhen Yi; Phuong Nguyen; Haley Houke; Matthew Bell; Dalia Haydar; Charmaine Brown; Shannon K Boi; Shanta Alli; Jeremy Chase Crawford; Janice M Riberdy; Jeoungeun J Park; Sheng Zhou; Mireya Paulina Velasquez; Chris DeRenzo; Cicera R Lazzarotto; Shengdar Q Tsai; Peter Vogel; Shondra M Pruett-Miller; Deanna M Langfitt; Stephen Gottschalk; Ben Youngblood; Giedre Krenciute
Journal:  Sci Transl Med       Date:  2021-11-17       Impact factor: 17.956

Review 3.  Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.

Authors:  Steven M Devine; Mary M Horowitz
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

4.  A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.

Authors:  Toshiki Ochi; Masaki Maruta; Kazushi Tanimoto; Fumitake Kondo; Toshihiro Yamamoto; Mie Kurata; Hiroshi Fujiwara; Junya Masumoto; Katsuto Takenaka; Masaki Yasukawa
Journal:  Commun Biol       Date:  2021-03-02

5.  Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors.

Authors:  Catherine T Le; William J Murphy
Journal:  J Immunother Cancer       Date:  2019-11-07       Impact factor: 13.751

6.  Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion.

Authors:  Jose M Ayuso; Shujah Rehman; Maria Virumbrales-Munoz; Patrick H McMinn; Peter Geiger; Cate Fitzgerald; Tiffany Heaster; Melissa C Skala; David J Beebe
Journal:  Sci Adv       Date:  2021-02-17       Impact factor: 14.136

7.  Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.

Authors:  Sabino Luzzi; Alice Giotta Lucifero; Ilaria Brambilla; Mariasole Magistrali; Mario Mosconi; Salvatore Savasta; Thomas Foiadelli
Journal:  Acta Biomed       Date:  2020-06-30

8.  Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.

Authors:  Christine Ambrose; Lihe Su; Lan Wu; Fay J Dufort; Thomas Sanford; Alyssa Birt; Benjamin J Hackel; Andreas Hombach; Hinrich Abken; Roy R Lobb; Paul D Rennert
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

9.  Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release.

Authors:  Xuan Liu; Jianyun Wen; Honglei Yi; Xiaorui Hou; Yue Yin; Guofu Ye; Xuedong Wu; Xiaotao Jiang
Journal:  Ther Adv Med Oncol       Date:  2020-03-09       Impact factor: 8.168

Review 10.  Investigating T Cell Immunity in Cancer: Achievements and Prospects.

Authors:  Zhen Zeng; Hui Yi Chew; Jazmina G Cruz; Graham R Leggatt; James W Wells
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.